癌性胸水LAK细胞的特性和抗肿瘤作用的观察

CHARACTERISTICS AND ANTITμMOR ACTIVITY OF LAK CELLS CμLTμRED FROM PLEμRAL EFFμSION OF CANCER PATIENTS

１７例癌性胸水经不连续密度梯度离心分离淋巴细胞，在ｒＩＬ－２诱导下体外培养，观察不同时期的ＬＡＫ细胞增殖速度、细胞表型和细胞毒活性，结果显示，胸水ＬＡＫ细胞在培养第１４天细胞扩增至原代的２０倍～８０倍，２１天后生长速度逐渐减慢。培养７天时对Ｋ５６２细胞和Ｒａｊｉ细胞的杀伤活性分别为７２％和６５％，以后随培养天数增加均呈逐渐下降趋势，但均高于同期培养的外周血ＬＡＫ细胞杀伤活性。培养７天～２１天间的细胞表型分析提示，ＣＤ＋３细胞百分率无明显改变，ＣＤ＋４细胞略增加，ＣＤ＋８细胞略有下降。ｒＩＬ－２／ＬＡＫ联合治疗肺癌胸水和肾癌胸水总有效率分别为５０％和６７％。

Lymphocytes were isolated from pleural effusion of 17 cancer patients by centrifugation on discontinuous density gradients. The rIL 2 activated lymphocytes were observed on their proliferation, phenotypes and cytotoxic activity at different inocubation intervals. The results indicated that effusion associated lymphocytes increased in cell number up to 20～80 times on the 14th day of incubation, and the proliferation rate of the cells began to slow down gradually around 21st day. The cytotoxicity of the cells against K562 and Raji cells were 72% and 65% respectively on the 7th day and then presented a tendency to decline gradually with cultivation. The cytotoxicity, however, was always higher than that of the LAK cells induced from PBL at the same time. The phenotypic analysis indicated that the ratio of CD + 3 cells kept unvaried while CD + 4 cells increased and CD + 8 cells decreased slightly. The total efficiency of the treatment with effusion associated rIL 2/LAK cells was found to be 50% and 67% for patients with lung cancer and kidney cancer respectively.